Ozempic may reduce the mortality risk from colon cancer — GLP-1 users were less than half as likely to die within 5 years

Dr. Rhonda Patrick shared new research showing GLP-1 drugs (Ozempic, Wegovy, Mounjaro) may specifically target obesity-driven inflammatory pathways, reducing colon cancer mortality by more than 50%.